Related content

Emerging BCR/ABL1 Mutations Under Treatment with Tyrosine Kinase Inhibitors in Paediatric Acute Lymphoblastic Leukaemia

By  

Acta Haematologica, Vol. 134, Iss. 2, 2015-04 ,pp. : 71-75

Karger

Access to resources Recommend Favorite

Acute Lymphoblastic Leukemia Expressing b3a2 (p210), e1a2 (p190), and Variant e1a2 BCR-ABL Transcripts: A Case Report and Review of the Literature

By  

Acta Haematologica, Vol. 128, Iss. 2, 2012-06 ,pp. : 119-123

Karger

Access to resources Recommend Favorite

A Rare, In-Frame BCR-ABL Fusion (e13a3) in a Patient with an Aggressive Chronic Myeloid Leukaemia

By  

Acta Haematologica, Vol. 108, Iss. 3, 2002-09 ,pp. : 150-153

Karger

Access to resources Recommend Favorite

BCR/ABL1 Kinase Domain Mutation Monitoring: Could Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Benefit As Well?

By  

Acta Haematologica, Vol. 134, Iss. 2, 2015-04 ,pp. : 69-70

Karger

Access to resources Recommend Favorite

A derivative of epigallocatechin‐3‐gallate induces apoptosis via SHP‐1‐mediated suppression of BCR‐ABL and STAT3 signalling in chronic myelogenous leukaemia

By  

BRITISH JOURNAL OF PHARMACOLOGY (ELECTRONIC), Vol. 172, Iss. 14, 2015-07 ,pp. : 3565-3578

John Wiley & Sons Inc

Access to resources Recommend Favorite